文献速递角膜与眼表疾病

SYL1001(一种新型短干扰RNA)治疗干眼症的安全性与有效性临床试验

Safety and Efficacy Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry Eye Disease.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2016-01-01

本研究合并一项I期和两项II期临床试验,在156名健康受试者和干眼症患者中测试不同剂量SYL1001。每日一次1.125% SYL1001滴眼较安慰剂显著降低VAS评分(第10天较基线变化-1.73±0.32 vs -0.91±0.34,P=0.013),结膜充血改善率50% vs 20%(P<0.05),耐受性良好。

要点

  • SYL1001 1.125%每日一次较安慰剂显著降低VAS评分(P=0.013)。
  • SYL1001 1.125%组结膜充血改善率50% vs 安慰剂组20%(P<0.05)。
  • 各治疗组OSDI评分较各自基线显著降低(P<0.01),组间无显著差异。

核心结论

  • 这些试验达到了主要终点,确定了SYL1001的最有效剂量为1.125%。
  • SYL1001显示出较大的安全边际,可能为缓解干眼提供新的治疗机会。

研究设计与样本

  • 本研究合并一项I期和两项II期临床试验,在共156名健康受试者和干眼症患者中测试不同剂量的SYL1001。
  • 治疗10天后,主要疗效终点为视觉模拟量表(VAS)和眼表疾病指数(OSDI)问卷评分的影响,以及通过角膜荧光素染色和结膜充血评估的眼部耐受性。
  • 次要终点包括全身和局部耐受性评估。

主要发现

  • 每日一次局部给予1.125% SYL1001从第4天至治疗结束较安慰剂显著降低VAS评分(第10天较基线变化:-1.73±0.32 vs -0.91±0.34;P=0.013)。
  • 所有治疗组OSDI评分较各自基线值显著降低(P<0.01),但组间未检测到显著变化。
  • 结膜充血(量化为正常或异常)在滴用1.125% SYL1001后较安慰剂显著改善(50% vs 20%;P<0.05)。
  • 报告了极好的耐受性,各组不良事件发生率无差异。

关键数值与推荐

  • 主要疗效终点包括VAS和OSDI问卷评分以及角膜荧光素染色和结膜充血评估的眼部耐受性。
  • SYL1001 1.125%每日一次较安慰剂显著降低VAS评分(第10天较基线变化:-1.73±0.32 vs -0.91±0.34;P=0.013)。
  • SYL1001 1.125%组结膜充血改善率50% vs 安慰剂组20%(P<0.05)。
  • 所有治疗组OSDI评分较各自基线显著降低(P<0.01),组间无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy and safety of SYL1001, a short interfering (si) RNA targeting the transient receptor potential cation channel subfamily V member 1 (TRPV1), for the treatment of dry eye disease (DED). METHODS: This study combines a phase I and two phase II clinical trials to test different doses of SYL1001 in a total of 156 healthy subjects and patients with DED. After 10 days of treatment, the primary efficacy endpoints were the effect on (1) the scoring in the Visual Analogue Scale (VAS) and Ocular Surface Disease Index (OSDI) questionnaires, and (2) ocular tolerance evaluated by corneal fluorescein staining and conjunctival hyperemia. Secondary endpoints included the assessment of systemic and local tolerance. RESULTS: Topical administration of SYL1001 1.125% once daily produced a significant decrease in VAS scores compared with placebo from day 4 until the end of treatment (change from baseline at day 10: -1.73 ± 0.32 vs. -0.91 ± 0.34; P = 0.013). For all treatments, OSDI scores were significantly reduced compared to their respective baseline values (P < 0.01), although no significant changes were detected between groups. Conjunctival hyperemia (quantified as normal or abnormal) significantly improved after instillation of SYL1001 1.125% compared with placebo (50% vs. 20%; P < 0.05). Excellent tolerability was reported, with no differences in the rates of occurrence of adverse events between groups. CONCLUSION: These trials achieved their primary endpoints of identifying the most effective dose of SYL1001 (1.125%). SYL1001 showed a large safety margin and may provide novel therapeutic opportunity for the relief of dry eye. (ClinicalTrials.gov numbers, NCT01438281, NCT01776658, and NCT02455999.).

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Benitez-Del-Castillo JM, Moreno-Montañés J, Jiménez-Alfaro I, et al. Safety and Efficacy Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry Eye Disease. Invest Ophthalmol Vis Sci. 2016. PMID: 27893109. doi:10.1167/iovs.16-20303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。